Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients
Status:
Terminated
Trial end date:
2018-10-25
Target enrollment:
Participant gender:
Summary
A rationally designed combination of adoptive T cell therapy and ipilimumab could strongly
increase the proportion of CR patients, as well as the durability of response, as compared to
ipilimumab or TIL alone. The investigators hypothesize that the combination of those two
important modalities could result in a durable (≥ 1 year) complete response rate of 30% in
stage IV melanoma patients.